Scale single-cell sequencing without compromising performance. Sansimeon’s platform uniquely scales single-cell sequencing, with the ability to directly process complex clinical samples.
Our Tools Accelerate Development of Breakthrough Therapies
Sansimeon is led by veterans in the life sciences industry, with a proven track record in bringing innovative technologies to market. Our products are based on ground breaking technologies developed at Massachusetts General Hospital, the largest teaching hospital of Harvard Medical School.
Unlock the Potential of Scaled Single-Cell Sequencing to Accelerate Cures
Fully characterize the immune response through TCR repertoire profiling to improve the efficacy of T-Cell immunotherapies and identify new therapeutics.
Perform genome-wide CRISPR screens to accelerate the development of CRISPR-based therapies.
Design personalized cancer treatments by identifying a person’s unique immune response to disease and to treatment.
Utilize cell engineering to design personalized cancer treatments with improved efficacy and at reduced cost.
Generate More High Quality Datasets for Drug Discovery Through Scaled, Cost-Effective & Streamlined Processing of Complex Clinical Samples
Generate multi-modal datasets with unprecedented resolution and scale to power machine learning in drug discovery and drug development.
Utilize single cell profiling of patient cohorts to identify clinically relevant signatures.
Discover new disease biomarkers and identify potential drug targets from single-cell sequencing data.
Generate multi-modal datasets with unprecedented resolution and scale to power machine learning in drug discovery and drug development.
